• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Anika Therapeutics Inc.

    3/26/26 3:45:54 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care
    Get the next $ANIK alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 8)


    Anika Therapeutics Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    035255108

    (CUSIP Number)
    03/13/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    035255108


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:   On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Anika Therapeutics Inc
    (b)Address of issuer's principal executive offices:

    32 Wiggins Avenue, Bedford, MA, 01730
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd.,, Malvern, PA, 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    0
    (b)Percent of class:

    0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:03/26/2026
    Get the next $ANIK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANIK

    DatePrice TargetRatingAnalyst
    4/17/2025$21.00Buy
    B. Riley Securities
    11/1/2024$37.00 → $25.00Outperform
    Barrington Research
    8/14/2023$24.00Mkt Perform → Outperform
    Barrington Research
    3/7/2023Outperform → Mkt Perform
    Barrington Research
    11/9/2022$31.00Mkt Perform → Outperform
    Barrington Research
    10/14/2022$26.00Equal-Weight
    Stephens
    3/9/2022Outperform → Mkt Perform
    Barrington Research
    3/9/2022Overweight → Equal-Weight
    Stephens & Co.
    More analyst ratings

    $ANIK
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Anika Therapeutics Inc.

    SCHEDULE 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    3/26/26 3:45:54 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Anika Therapeutics, Inc. (0000898437) (Filer)

    2/26/26 7:18:31 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Anika Therapeutics, Inc. (0000898437) (Filer)

    1/8/26 4:02:04 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Mcleod Ian

    4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

    3/23/26 5:23:05 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    EVP, General Counsel, Corp Sec Colleran David converted options into 15,837 shares, was granted 4,694 shares and covered exercise/tax liability with 6,061 shares, increasing direct ownership by 27% to 67,570 units (SEC Form 4)

    4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

    3/17/26 7:47:22 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    President and CEO Griffin Stephen D. was granted 6,412 shares, covered exercise/tax liability with 5,944 shares and converted options into 12,824 shares, increasing direct ownership by 125% to 23,963 units (SEC Form 4)

    4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

    3/17/26 7:44:08 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anika Reports Fourth Quarter and Full Year 2025 Financial Results

    Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 million operating cash flow and $4.4 million in free cash flow for the full year FDA response for Hyalofast® PMA received in January 2026, Anika developing responses for submission BEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the fourth quarter and full year ended December 3

    2/26/26 7:05:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference

    BEDFORD, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that Steve Griffin, President and CEO of Anika, will present at the Canaccord Genuity 2026 Musculoskeletal Conference in New Orleans on Monday, March 2, 2026 at 11:30am CT / 12:30pm ET. Management will also participate in one-on-one investor meetings throughout the event. The presentation will be webcast live on the Events and Webcasts page under the Investors section of Anika Therapeutics' website and will be archived for 30 days following the presentation. For more information about this event or to schedule a on

    2/18/26 4:01:00 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026

    BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2025 financial results before the opening of the market on Thursday, February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 89327. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's

    2/12/26 4:01:00 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Anika Therapeutics with a new price target

    B. Riley Securities initiated coverage of Anika Therapeutics with a rating of Buy and set a new price target of $21.00

    4/17/25 8:32:06 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Barrington Research reiterated coverage on Anika Therapeutics with a new price target

    Barrington Research reiterated coverage of Anika Therapeutics with a rating of Outperform and set a new price target of $25.00 from $37.00 previously

    11/1/24 10:25:08 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Therapeutics upgraded by Barrington Research with a new price target

    Barrington Research upgraded Anika Therapeutics from Mkt Perform to Outperform and set a new price target of $24.00

    8/14/23 9:16:10 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Leadership Updates

    Live Leadership Updates

    View All

    Lumicell Appoints Biotech and Medtech Leader Cheryl R. Blanchard, Ph.D., to Board of Directors

    NEWTON, Mass., Feb. 4, 2026 /PRNewswire/ -- Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies for cancer detection, today announced the appointment of Cheryl R. Blanchard, Ph.D., to its Board of Directors. Dr. Blanchard is an accomplished biotech and medtech CEO and board member with more than 30 years of experience building, scaling, and transforming public and private life sciences companies. Dr. Blanchard most recently served as President, CEO, and Director of Anika Therapeutics (NASDAQ:ANIK), where she led the successful implementat

    2/4/26 8:54:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Therapeutics Announces Leadership Transition

    Stephen (Steve) Griffin, Current Chief Financial Officer and Chief Operating Officer, Appointed President and Chief Executive OfficerCheryl Blanchard to Become Executive Chair of the Board of Directors BEDFORD, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that Stephen (Steve) Griffin, current Executive Vice President, Chief Financial Officer and Chief Operating Officer, has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective February 1, 2026. Mr. Griff

    1/8/26 7:00:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

    Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

    6/26/24 8:00:00 AM ET
    $A
    $ANIK
    $AVNT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical/Dental Instruments
    Health Care

    $ANIK
    Financials

    Live finance-specific insights

    View All

    Anika Reports Fourth Quarter and Full Year 2025 Financial Results

    Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 million operating cash flow and $4.4 million in free cash flow for the full year FDA response for Hyalofast® PMA received in January 2026, Anika developing responses for submission BEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the fourth quarter and full year ended December 3

    2/26/26 7:05:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026

    BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2025 financial results before the opening of the market on Thursday, February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 89327. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's

    2/12/26 4:01:00 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Reports Third Quarter 2025 Financial Results

    Commercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module filed and data released Cingal® achieved commercial milestone of more than one million injections worldwide since 2016 Reaffirming Fiscal 2025 guidance and long-term outlook and commencing a $15 million 10b5-1 share repurchase BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced financial results for th

    11/5/25 7:05:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Anika Therapeutics Inc.

    SC 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    11/8/24 2:17:24 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Anika Therapeutics Inc. (Amendment)

    SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    5/30/24 4:31:25 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Anika Therapeutics Inc. (Amendment)

    SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    3/6/24 7:30:09 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care